Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.

Documents On Display - Continuing Connected Transactions - Renewal Of The Sinopharm Distribution Collaboration

Proxy Form For The 2025 Fourth Extraordinary General Meeting
To Be Held On 31 December 2025 (Or Any Adjournment Thereof)

Announcements and Notices - [Notice of EGM/SGM / Closure of Books or Change of Book Closure Period]

Notice Of Extraordinary General Meeting

Circulars - [Continuing Connected Transaction]

Continuing Connected Transactions
Renewal Of The Sinopharm Distribution Collaboration
And
Notice Of Extraordinary General Meeting

Announcements and Notices - [Continuing Connected Transaction]

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Documents On Display - Continuing Connected Transactions - Renewal Of The Sinopharm Distribution Collaboration

Proxy Form For The 2025 Fourth Extraordinary General Meeting To Be Held On 31 December 2025 (Or Any Adjournment Thereof)

Notice Of Extraordinary General Meeting

Continuing Connected Transactions Renewal Of The Sinopharm Distribution Collaboration And Notice Of Extraordinary General Meeting

Continuing Connected Transactions - Renewal Of The Sinopharm Distribution Collaboration